[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2] Morgan E, Arnold M, Camargo MC, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: a population-based modelling study[J]. eClinical Medicine, 2022, 47: 101404.
[3] Jiang XJ, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease[J]. Nat Rev Mol Cell Biol, 2021, 22(4): 266-282.
[4] Koppula P, Zhuang L, Gan BY. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy[J]. Protein Cell, 2021, 12(8): 599-620.
[5] Zhao L, Zhou XX, Xie F, et al. Ferroptosis in cancer and cancer immunotherapy[J]. Cancer Commun (Lond), 2022, 42(2): 88-116.
[6] Zhang C, Liu XY, Jin SD, et al. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance[J]. Mol Cancer, 2022, 21(1): 47.
[7] Zhang HL, Hu BX, Li ZL, et al. PKCβII phosphorylates ACSL4 to amplify lipid peroxidation to induce ferroptosis[J]. Nat Cell Biol, 2022, 24(1): 88-98.
[8] Sun YT, Chen P, Zhai BT, et al. The emerging role of ferroptosis in inflammation[J]. Biomed Pharmacother, 2020, 127: 110108.
[9] Liu MR, Zhu WT, Pei DS. System Xc-: a key regulatory target of ferroptosis in cancer[J]. Invest New Drugs, 2021, 39(4): 1123-1131.
[10] Kong R, Wang N, Han W, et al. IFNγ-mediated repression of System Xc- drives vulnerability to induced ferroptosis in hepatocellular carcinoma cells[J]. J Leukoc Biol, 2021, 110(2): 301-314.
[11] Li FJ, Long HZ, Zhou ZW, et al. System Xc-/ GSH/GPX4 axis: an important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy[J]. Front Pharmacol, 2022, 13: 910292.
[12] Sears SM, Hewett SJ. Influence of glutamate and GABA transport on brain excitatory/inhibitory balance[J]. Exp Biol Med (Maywood), 2021, 246(9): 1069-1083.
[13] Du Y, Guo Z. Recent progress in ferroptosis: inducers and inhibitors[J]. Cell Death Discov, 2022, 8(1): 501.
[14] Korbecki J, Bosiacki M, Barczak K, et al. The clinical significance and role of CXCL1 chemokine in gastrointestinal cancers[J]. Cells, 2023, 12(10): 1406.
[15] Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer[J]. Lancet, 2019, 394(10207): 1467-1480.
[16] 马涛, 黄玮玮, 于湘友. System Xc-/GPX4/Nrf2介导的铁死亡对脓毒症大鼠肠道机械屏障的影响[J]. 中华实用诊断与治疗杂志, 2024, 38(1): 12-18.
[17] 朱明镒. SLC7A11在结直肠癌中的表达及其与微卫星不稳定的相关性研究[D]. 承德: 承德医学院, 2022.
[18] Feng LF, Li MC, Hu XY, et al. CK1δ stimulates ubiquitination-dependent proteasomal degradation of ATF4 to promote chemoresistance in gastric Cancer[J]. Clin Transl Med, 2021, 11(10): e587.
[19] Loong JH, Wong TL, Tong M, et al. Glucose deprivation-induced aberrant FUT1-mediated fucosylation drives cancer stemness in hepatocellular carcinoma[J]. J Clin Invest, 2021, 131(11): e143377.
[20] Kato Y, Kunimasa K, Takahashi M, et al. GZD824 inhibits GCN2 and sensitizes cancer cells to amino acid starvation stress[J]. Mol Pharmacol, 2020, 98(6): 669-676.
[21] Yang YB, Zhou JX, Qiu SH, et al. Identification of a novel ferroptosis-related gene prediction model for clinical prognosis and immunotherapy of colorectal cancer[J]. Dis Markers, 2021, 2021: 4846683.
[22] Yang JF, Zhang QY, Huang GL, et al. Combined effects of vitamin D and neferine on the progression and metastasis of colorectal cancer[J]. J Cancer Res Clin Oncol, 2023, 149(9): 6203-6210.
[23] Guo S, Zhao W, Zhang WH, et al. Vitamin D promotes ferroptosis in colorectal cancer stem cells via SLC7A11 downregulation[J]. Oxid Med Cell Longev, 2023, 2023: 4772134.
[24] Liu B, Wang H. Oxaliplatin induces ferroptosis and oxidative stress in HT29 colorectal cancer cells byinhibiting the Nrf2 signaling pathway[J]. Exp Ther Med. 2022, 23(6): 394.
[25] Li YM, Gan YQ, Liu JX, et al. Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer[J]. Sig Transduct Target Ther, 2022, 7: 87.
[26] 徐磊, 武寒, 王苗苗, 等. 干预自噬调控p62-Keap1/Nrf2-GPX4通路对结直肠癌细胞铁死亡及奥沙利铂耐药的影响[J]. 临床与实验病理学杂志, 2024, 40(2): 133-144.
[27] Xia Y, Xia Y, Liu S, et al. Discovery of a novel ferroptosis inducer-talaroconvolutin A-killing colorectal cancer cells in vitro and in vivo[J]. Cell Death Dis, 2020, 11(11): 988.
[28] Zhang L, Liu W, Liu FY, et al. IMCA induces ferroptosis mediated by SLC7A11 through the AMPK/mTOR pathway in colorectal cancer[J]. Oxid Med Cell Longev, 2020, 2020: 1675613.
[29] Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention[J]. Nat Rev Clin Oncol, 2023, 20(5): 338-349.
[30] Koppula P, Zhuang L, Gan BY. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy[J]. Protein Cell, 2021, 12(8): 599-620.
[31] Chang LC, Chiang SK, Chen SE, et al. Heme oxygenase-1 mediates BAY 11-7085 induced ferroptosis[J]. Cancer Lett, 2018, 416: 124-137.
[32] Su H, Peng C, Liu Y. Regulation of ferroptosis by PI3K/Akt signaling pathway: a promising therapeutic axis in cancer[J]. Front Cell Dev Biol, 2024, 12: 1372330.
[33] Jiang Y, Cui JY, Cui M, et al. SLC7A11 promotes the progression of gastric cancer and regulates ferroptosis through PI3K/AKT pathway[J]. Pathol Res Pract, 2023, 248: 154646.
[34] Dai ZT, Wu YL, Li XR, et al. MKL-1 suppresses ferroptosis by activating system Xc- and increasing glutathione synthesis[J]. Int J Biol Sci, 2023, 19(14): 4457-4475.
[35] Boyce M, Bryant KF, Jousse C, et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress[J]. Science, 2005, 307(5711): 935-939.
[36] Guan ZH, Chen J, Li XL, et al. Tanshinone IIA induces ferroptosis in gastric cancer cells through p53-mediated SLC7A11 down-regulation[J]. Biosci Rep, 2020, 40(8): BSR20201807.
[37] Mao SH, Zhu CH, Nie Y, et al. Levobupivacaine induces ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer[J]. Front Pharmacol, 2021, 12: 681338.
[38] Tang X, Chen W, Liu H, et al. Research progress on SLC7A11 in the regulation of cystine/cysteine metabolism in tumors[J]. Oncol Lett, 2022, 23(2): 47.
[39] 刘威龙, 张明霞, 郑娟, 等. 溶质载体家族7成员11基因SLC7A11与肝癌临床特征相关性[J]. 中国热带医学, 2021, 21(6): 559-561, 575.
[40] Huang ML, Wang Y, Wu XW, et al. Crosstalk between endoplasmic reticulum stress and ferroptosis in liver diseases[J]. Front Biosci (Landmark Ed), 2024, 29(6): 221.
[41] Lee Y, Itahana Y, Ong CC, et al. Redox-dependent AMPK inactivation disrupts metabolic adaptation to glucose starvation in xCT-overexpressing cancer cells[J]. J Cell Sci, 2022, 135(15): jcs259090.
[42] Ye P, Mimura J, Okada T, et al. Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition[J]. Mol Cell Biol, 2014, 34(18): 3421-3434.
[43] 王苗, 孟婉蓉, 李龙江. 基于胱氨酸-谷氨酸反向转运体的抗肿瘤代谢治疗新策略[J]. 国际口腔医学杂志, 2024, 51(1): 10-20.
[44] Lee SY, Kim HS, Kim MJ, et al. Glutamine metabolite α-ketoglutarate acts as an epigenetic co-factor to interfere with osteoclast differentiation[J]. Bone, 2021, 145: 115836.
[45] Wu J, Minikes AM, Gao M, et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling[J]. Nature, 2019, 572(7769): 402-406.
[46] Gao RZ, Kalathur RKR, Coto-Llerena M, et al. YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis[J]. EMBO Mol Med, 2021, 13(12): e14351.
[47] Cheng AL, Kang YK, Chen ZD, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
[48] Wang L, Wang J, Chen L. TIMP1 represses sorafenib-triggered ferroptosis in colorectal cancer cells by activating the PI3K/Akt signaling pathway[J]. Immunopharmacol Immunotoxicol, 2023, 45(4): 419-425.
[49] Yuan SY, Wei C, Liu GF, et al. Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF-1α/SLC7A11 pathway[J]. Cell Prolif, 2022, 55(1): e13158.
[50] Iseda N, Itoh S, Toshida K, et al. Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma[J]. Cancer Sci, 2022, 113(7): 2272-2287.
[51] Zeng KX, Huang N, Liu NB, et al. LACTB suppresses liver cancer progression through regulation of ferroptosis[J]. Redox Biol, 2024, 75: 103270.
